215 related articles for article (PubMed ID: 17593021)
21. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
Klastersky J; Awada A; Aoun M; Paesmans M
Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
[TBL] [Abstract][Full Text] [Related]
22. Febrile neutropenia in haematological malignancies.
Sharma A; Lokeshwar N
J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
24. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
Timmer-Bonte JN; Tjan-Heijnen VC
Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
[TBL] [Abstract][Full Text] [Related]
25. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
[TBL] [Abstract][Full Text] [Related]
26. Colony-stimulating factors in the management of neutropenia and its complications.
Heuser M; Ganser A
Ann Hematol; 2005 Oct; 84(11):697-708. PubMed ID: 16047204
[TBL] [Abstract][Full Text] [Related]
27. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I.
Mego M; Ebringer L; Drgona L; Mardiak J; Trupl J; Greksak R; Nemova I; Oravcova E; Zajac V; Koza I
Neoplasma; 2005; 52(2):159-64. PubMed ID: 15800715
[TBL] [Abstract][Full Text] [Related]
28. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
[TBL] [Abstract][Full Text] [Related]
29. [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics].
Gharbi O; Ben Hadj Hassen S; Kaabia N; Limam S; Hadj Amor M; Ben Fatma L; Landolsi A; Hochlef M; Letaief A; Boukadida J; Ben Ahmed S
Pathol Biol (Paris); 2008 May; 56(3):154-7. PubMed ID: 18178025
[TBL] [Abstract][Full Text] [Related]
30. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
Lyman GH; Kuderer NM
Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
[TBL] [Abstract][Full Text] [Related]
32. Risk assessment in oncology clinical practice. From risk factors to risk models.
Lyman GH
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
[TBL] [Abstract][Full Text] [Related]
33. Myeloid growth factors.
Crawford J; Allen J; Armitage J; Blayney DW; Cataland SR; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; McMahon B; Steensma DP; Vadhan-Raj S; Westervelt P; Westmoreland M;
J Natl Compr Canc Netw; 2011 Aug; 9(8):914-32. PubMed ID: 21900221
[No Abstract] [Full Text] [Related]
34. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
35. Malaria parasitemia associated with febrile neutropenia in African patients undergoing chemotherapy for haematological malignancies. A report of three patients.
Rapoport BL; Uys A
Chemotherapy; 2008; 54(2):117-9. PubMed ID: 18303260
[TBL] [Abstract][Full Text] [Related]
36. Drug therapy management of the febrile neutropenic cancer patient.
Finkbiner KL; Ernst TF
Cancer Pract; 1993; 1(4):295-304. PubMed ID: 8111439
[TBL] [Abstract][Full Text] [Related]
37. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
Crawford J; Dale DC; Lyman GH
Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
40. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
Gil L; Styczynski J; Komarnicki M
Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
